|
WO2019210035A1
|
|
Methods of treating excitotoxicity disorders
|
|
US2017135968A1
|
|
Methods for storing cysteamine formulations and related methods of treatment
|
|
AU2016298324A1
|
|
Fucosidase inhibitors
|
|
BR112017028448A2
|
|
ado-resistant cysteamine analogs and uses thereof
|
|
TW201534357A
|
|
Delayed release cysteamine bead formulation, and preparation and use thereof
|
|
TW201534920A
|
|
Methods for analyzing cysteamine compositions
|
|
AU2013203605A1
|
|
Aerosolized fluoroquinolones and uses thereof
|
|
EP2774612A1
|
|
4-Methylpyrazole formulations
|
|
EP2473170A1
|
|
Use of aerosolized levofloxacin for treating cystic fibrosis
|
|
EP3311811A1
|
|
Genotype specific methods for treating human subjects using 4- methylpyrazole
|
